Evaluation of walking activity and gait to identify physical and mental fatigue in neurodegenerative and immune disorders: preliminary insights from the IDEA-FAST feasibility study
-
Published:2024-06-05
Issue:1
Volume:21
Page:
-
ISSN:1743-0003
-
Container-title:Journal of NeuroEngineering and Rehabilitation
-
language:en
-
Short-container-title:J NeuroEngineering Rehabil
Author:
Hinchliffe Chloe,Rehman Rana Zia Ur,Pinaud Clemence,Branco Diogo,Jackson Dan,Ahmaniemi Teemu,Guerreiro Tiago,Chatterjee Meenakshi,Manyakov Nikolay V.,Pandis Ioannis,Davies Kristen,Macrae Victoria,Aufenberg Svenja,Paulides Emma,Hildesheim Hanna,Kudelka Jennifer,Emmert Kirsten,Van Gassen Geert,Rochester Lynn,van der Woude C. Janneke,Reilmann Ralf,Maetzler Walter,Ng Wan-Fai,Del Din Silvia,
Abstract
Abstract
Background
Many individuals with neurodegenerative (NDD) and immune-mediated inflammatory disorders (IMID) experience debilitating fatigue. Currently, assessments of fatigue rely on patient reported outcomes (PROs), which are subjective and prone to recall biases. Wearable devices, however, provide objective and reliable estimates of gait, an essential component of health, and may present objective evidence of fatigue. This study explored the relationships between gait characteristics derived from an inertial measurement unit (IMU) and patient-reported fatigue in the IDEA-FAST feasibility study.
Methods
Participants with IMIDs and NDDs (Parkinson's disease (PD), Huntington's disease (HD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjogren’s syndrome (PSS), and inflammatory bowel disease (IBD)) wore a lower-back IMU continuously for up to 10 days at home. Concurrently, participants completed PROs (physical fatigue (PF) and mental fatigue (MF)) up to four times a day. Macro (volume, variability, pattern, and acceleration vector magnitude) and micro (pace, rhythm, variability, asymmetry, and postural control) gait characteristics were extracted from the accelerometer data. The associations of these measures with the PROs were evaluated using a generalised linear mixed-effects model (GLMM) and binary classification with machine learning.
Results
Data were recorded from 72 participants: PD = 13, HD = 9, RA = 12, SLE = 9, PSS = 14, IBD = 15. For the GLMM, the variability of the non-walking bouts length (in seconds) with PF returned the highest conditional R2, 0.165, and with MF the highest marginal R2, 0.0018. For the machine learning classifiers, the highest accuracy of the current analysis was returned by the micro gait characteristics with an intrasubject cross validation method and MF as 56.90% (precision = 43.9%, recall = 51.4%). Overall, the acceleration vector magnitude, bout length variation, postural control, and gait rhythm were the most interesting characteristics for future analysis.
Conclusions
Counterintuitively, the outcomes indicate that there is a weak relationship between typical gait measures and abnormal fatigue. However, factors such as the COVID-19 pandemic may have impacted gait behaviours. Therefore, further investigations with a larger cohort are required to fully understand the relationship between gait and abnormal fatigue.
Funder
EU Innovative Medicines Initiative 2 Joint Undertaking National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre NIHR/Wellcome Trust Clinical Research Facility
Publisher
Springer Science and Business Media LLC
Reference75 articles.
1. Tench CM, McCurdie I, White PD, D’Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford). 2000;39(11):1249–54. 2. Dima A, Caraiola S, Delcea C, Ionescu RA, Jurcut C, Badea C. Self-reported disease severity in women with systemic lupus erythematosus. Rheumatol Int. 2019;39(3):533–9. 3. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, et al. Fatigue in Parkinson’s disease: a review. Mov Disord. 2007;22(3):297–308. 4. Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, et al. Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren’s syndrome. Arthritis Rheum. 2008;59(12):1780–7. 5. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol. 1996;23(8):1407–17.
|
|